Azeria Therapeutics has wound down voluntarily four years after being set up to advance University of Cambridge and Cancer Research UK work.
Azeria Therapeutics, a UK-based oncology spinout of University of Cambridge and research charity Cancer Research UK (CRUK), has wound down voluntarily and returned “a substantial amount of funds” to investors, according to BusinessWeekly.
The spinout formally made the decision to halt operations in December 2020, according to a regulatory filing, and had appointed Stephen Adshead of Smith & Williamson as the liquidator.
Shareholder Syncona had already revealed its decision to write off its investment the previous month…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.